

**IN THE CLAIMS:**

**Please cancel claims 16-19 without prejudice.**

**Please add the following claims:**

16. An isolated antibody generated using an IL-13 receptor  $\alpha$ -chain polypeptide comprising all or part of SEQ ID NO: 4, which antibody binds to an IL-13 receptor  $\alpha$ -chain.

17. An isolated antibody which binds specifically to an IL-13 receptor  $\alpha$ -chain consisting of the sequence of SEQ ID NO: 4.

18. The isolated antibody according to claim 16 or 17, wherein said antibody inhibits the interaction between IL-13 and an IL-13 receptor  $\alpha$ -chain.

19. The isolated antibody according to claim 16 or 17, wherein said antibody inhibits the interaction between IL-13 and an IL-13 receptor  $\alpha$ -chain consisting of the sequence of SEQ ID NO: 4.

20. The isolated antibody according to claim 16 or 17, wherein said antibody inhibits the interaction between an IL-13 receptor  $\alpha$ -chain and an IL-4 receptor  $\alpha$ -chain.

21. The isolated antibody according to claim 16 or 17, wherein said antibody is a polyclonal antibody.

22. The isolated antibody according to claim 16 or 17, wherein said antibody is a monoclonal antibody.

23. A pharmaceutical composition comprising the antibody according to claim 16 or 17 and at least one of a pharmaceutically acceptable carrier or a diluent.

24. A pharmaceutical composition comprising the antibody according to claim 18 and at least one of a pharmaceutically acceptable carrier or a diluent.

45. A pharmaceutical composition comprising the antibody according to claim 39 and at least one of a pharmaceutically acceptable carrier or a diluent.

46. A pharmaceutical composition comprising the antibody according to claim 40 and at least one of a pharmaceutically acceptable carrier or a diluent.

47. A pharmaceutical composition comprising the antibody according to claim 41 and at least one of a pharmaceutically acceptable carrier or a diluent.

48. A pharmaceutical composition comprising the antibody according to claim 42 and at least one of a pharmaceutically acceptable carrier or a diluent.

14  
49. An isolated antibody against an IL-13 receptor  $\alpha$ -chain or an antigen-binding fragment thereof, wherein said antibody or said antigen-binding fragment binds SEQ ID NO: 4.

15  
50 The isolated antibody or antigen-binding fragment of claim 49, wherein said IL-13 receptor  $\alpha$ -chain consists of SEQ ID NO: 4.

### REMARKS

In the Office Action dated October 31, 2002, claims 16-19 are pending. Claims 18-19 are under consideration and claims 16-17 have been withdrawn from consideration. Claims 18 and 19 have been rejected under 35 U.S.C. §101 as allegedly directed to non-statutory subject matter. Claims 18 and 19 are further rejected under the enablement and written description requirements of 35 U.S.C. §112, first paragraph. The application is also objected to for certain informalities.

This Response addresses each of the Examiner's rejections and objections. Applicants therefore respectfully submit that the present application is in condition for allowance. Favorable consideration of all pending claims is therefore respectfully requested.